サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1657972

セラノスティクス市場の評価：製品別、用途別、技術別、エンドユーザー別、地域別、機会および予測、2018～2032年

Theranostics Market Assessment, By Product, By Application, By Technology, By End-user, By Region, Opportunities and Forecast, 2018-2032F

出版日
ページ情報
英文 225 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
セラノスティクス市場の評価：製品別、用途別、技術別、エンドユーザー別、地域別、機会および予測、2018～2032年
出版日: 2025年02月19日
発行: Market Xcel - Markets and Data
ページ情報: 英文 225 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のセラノスティクスは、2025～2032年の予測期間中にCAGR 14.20％を記録し、2024年の23億1,000万米ドルから2032年には66億8,000万米ドルに成長すると予測されています。セラノスティクス市場は、慢性疾患、特にがんの罹患率の増加、投資の増加、標的医療に対する需要の高まりに牽引され、革命的な活況を呈そうとしています。診断法と治療法の進歩も治療の精度を高める一方、強力なヘルスケア・インフラと政策支援が、この急成長分野のイノベーションと利用可能性を促進しています。

特に大学病院におけるセラノスティクスへの投資と融資の増加は、個別化医療における革新的な進歩を可能にし、市場の成長を促進しています。これらの資金は、新しい診断技術や標的治療薬の創出に拍車をかけるとともに、トランスレーショナルリサーチを促進しています。資金援助はまた、官民パートナーシップを助け、規制機関からの承認を加速し、セラノスティック・ソリューションへのアクセスを増加させています。2024年9月、カロリンスカ研究所のセラノスティクス・トライアル・センターは、スウェーデンのイノベーション政府機関であるVinnovaから140万米ドルの助成を受けた。同研究所は、画像誘導診断と放射性標識標的薬によってスウェーデンのがん治療に革命を起こすことを目指しており、セラノスティクス市場の成長機会を強調しています。投資の増加は、精密ヘルスケアに向けた世界の動きを示すものであり、市場成長と患者の治療成績向上のための大きな機会を提供するものです。

個別化治療に対するニーズの高まりは、セラノスティクス市場の成長を促す主な要因の一つであり、セラノスティクス新製品のイントロダクションよって支えられています。2024年10月、Mediso Kft.はEANM会議でAnyScan TRIO SPECT/CT、TheraMAXを発表しました。これはセラノスティックイメージングを目的としたもので、当初はドイツのレーゲンスブルク大学病院に設置されました。このリリースは、PET/CTのように診断の信頼性を向上させるもので、核医学部門のイメージング能力を拡大することにより、セラノスティクス市場の大幅な成長を示しています。精密医療に向けたこの動向は、規制環境の強化や製薬会社と研究機関のパートナーシップの増加によってさらに後押しされ、セラノスティクスを個別化医療に不可欠な戦略とし、より大きな市場機会を生み出しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のセラノスティクス市場の展望、2018年～2032年

  • 市場規模の分析と予測
    • 金額別
  • 市場シェア分析と予測
    • 製品別
      • 放射性医薬品
      • 診断画像
      • ソフトウェアとサービス
    • 用途別
      • 腫瘍学
      • 心血管疾患
      • 神経疾患
      • 免疫疾患
      • その他の用途
    • 技術別
      • ポリメラーゼ連鎖反応（PCR）
      • 免疫組織化学（IHC）
      • インサイチューハイブリダイゼーション（ISH）
      • 次世代シーケンシング（NGS）
    • エンドユーザー別
      • 病院
      • がんケアセンター
      • 診断検査室
      • 調査・学術センター
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • 南米
      • 中東およびアフリカ
    • 市場シェア分析（上位5社およびその他- 金額別、2024年）、企業別
  • 市場マップ分析、2024年
    • 製品別
    • 用途別
    • 技術別
    • エンドユーザー別
    • 地域別

第5章 北米のセラノスティクス市場の展望、2018年～2032年

  • 市場規模の分析と予測
    • 金額別
  • 市場シェア分析と予測
    • 製品別
      • 放射性医薬品
      • 診断画像
      • ソフトウェアとサービス
    • 用途別
      • 腫瘍学
      • 心血管疾患
      • 神経疾患
      • 免疫疾患
      • その他の用途
    • 技術別
      • ポリメラーゼ連鎖反応（PCR）
      • 免疫組織化学（IHC）
      • インサイチューハイブリダイゼーション（ISH）
      • 次世代シーケンシング（NGS）
    • エンドユーザー別
      • 病院
      • がんケアセンター
      • 診断検査室
      • 調査・学術センター
    • 国別シェア
      • 米国
      • カナダ
      • メキシコ
  • 国別市場評価
    • 米国のセラノスティクス市場の展望、2018～2032年
      • 市場規模の分析と予測
      • 市場シェア分析と予測
    • カナダ
    • メキシコ

すべてのセグメントは、対象となるすべての地域と国で提供されます。

第6章 欧州のセラノスティクス市場の展望、2018年～2032年

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • ポーランド

第7章 アジア太平洋のセラノスティクス市場の展望、2018年～2032年

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第8章 南米のセラノスティクス市場の展望、2018年～2032年

  • ブラジル
  • アルゼンチン

第9章 中東およびアフリカのセラノスティクス市場の展望、2018年～2032年

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ
  • イスラエル

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

  • 市場促進要因
  • 市場の課題

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

  • 臨床試験
  • 規制当局の承認

第18章 特許の情勢

第19章 ケーススタディ

第20章 競合情勢

  • 市場リーダー上位5社の競合マトリックス
  • 上位5社のSWOT分析
  • 市場上位10社の主要企業の情勢
    • Siemens Healthineers AG
      • 会社概要
      • 主要経営陣
      • 製品とサービス
      • 財務状況（報告通り）
      • 主な市場フォーカスと地理的プレゼンス
      • 最近の動向/コラボレーション/ パートナーシップ/合併と買収
    • Cardinal Health Inc.
    • GE HealthCare Technologies Inc.
    • Telix Pharmaceuticals Limited
    • Jubilant Pharmova Limited（Jubilant Radiopharma）
    • Radiopharm Theranostics Limited
    • Lantheus Holdings, Inc.
    • Curium Pharma UK Ltd
    • Cardio Theranostics LLC
    • Ariceum Therapeutics GmbH

上記の企業は市場シェアに基づいて注文を保留しておらず、調査作業中に入手可能な情報に基づいて変更される可能性があります。

第21章 戦略的提言

第22章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 3. Global Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 4. Global Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 5. Global Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 6. Global Theranostics Market Share (%), By Region, 2018-2032F
  • Figure 7. North America Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 8. North America Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 9. North America Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 10. North America Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 11. North America Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 12. North America Theranostics Market Share (%), By Country, 2018-2032F
  • Figure 13. United States Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 14. United States Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 15. United States Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 16. United States Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 17. United States Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 18. Canada Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 19. Canada Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 20. Canada Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 21. Canada Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 22. Canada Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 23. Mexico Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Mexico Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 25. Mexico Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 26. Mexico Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 27. Mexico Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 28. Europe Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Europe Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 30. Europe Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 31. Europe Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 32. Europe Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 33. Europe Theranostics Market Share (%), By Country, 2018-2032F
  • Figure 34. Germany Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 35. Germany Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 36. Germany Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 37. Germany Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 38. Germany Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 39. France Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 40. France Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 41. France Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 42. France Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 43. France Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 44. Italy Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Italy Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 46. Italy Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 47. Italy Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 48. Italy Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 49. United Kingdom Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 50. United Kingdom Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 51. United Kingdom Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 52. United Kingdom Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 53. United Kingdom Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 54. Russia Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 55. Russia Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 56. Russia Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 57. Russia Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 58. Russia Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 59. Netherlands Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 60. Netherlands Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 61. Netherlands Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 62. Netherlands Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 63. Netherlands Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 64. Spain Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Spain Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 66. Spain Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 67. Spain Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 68. Spain Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 69. Turkey Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Turkey Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 71. Turkey Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 72. Turkey Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 73. Turkey Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 74. Poland Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 75. Poland Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 76. Poland Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 77. Poland Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 78. Poland Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 79. South America Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 80. South America Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 81. South America Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 82. South America Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 83. South America Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 84. South America Theranostics Market Share (%), By Country, 2018-2032F
  • Figure 85. Brazil Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 86. Brazil Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 87. Brazil Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 88. Brazil Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 89. Brazil Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 90. Argentina Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Argentina Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 92. Argentina Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 93. Argentina Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 94. Argentina Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 95. Asia-Pacific Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 96. Asia-Pacific Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 97. Asia-Pacific Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 98. Asia-Pacific Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 99. Asia-Pacific Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 100. Asia-Pacific Theranostics Market Share (%), By Country, 2018-2032F
  • Figure 101. India Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 102. India Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 103. India Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 104. India Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 105. India Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 106. China Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. China Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 108. China Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 109. China Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 110. China Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 111. Japan Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 112. Japan Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 113. Japan Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 114. Japan Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 115. Japan Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 116. Australia Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 117. Australia Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 118. Australia Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 119. Australia Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 120. Australia Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 121. Vietnam Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 122. Vietnam Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 123. Vietnam Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 124. Vietnam Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 125. Vietnam Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 126. South Korea Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 127. South Korea Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 128. South Korea Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 129. South Korea Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 130. South Korea Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 131. Indonesia Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 132. Indonesia Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 133. Indonesia Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 134. Indonesia Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 135. Indonesia Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 136. Philippines Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 137. Philippines Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 138. Philippines Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 139. Philippines Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 140. Philippines Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 141. Middle East & Africa Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 142. Middle East & Africa Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 143. Middle East & Africa Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 144. Middle East & Africa Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 145. Middle East & Africa Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 146. Middle East & Africa Theranostics Market Share (%), By Country, 2018-2032F
  • Figure 147. Saudi Arabia Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 148. Saudi Arabia Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 149. Saudi Arabia Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 150. Saudi Arabia Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 151. Saudi Arabia Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 152. UAE Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 153. UAE Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 154. UAE Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 155. UAE Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 156. UAE Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 157. South Africa Theranostics Market, By Value, In USD Billion, 2018-2032F
  • Figure 158. South Africa Theranostics Market Share (%), By Product, 2018-2032F
  • Figure 159. South Africa Theranostics Market Share (%), By Application, 2018-2032F
  • Figure 160. South Africa Theranostics Market Share (%), By Technology, 2018-2032F
  • Figure 161. South Africa Theranostics Market Share (%), By End-user, 2018-2032F
  • Figure 162. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 163. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 164. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 165. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024
目次
Product Code: MX12754

Global theranostics is projected to witness a CAGR of 14.20% during the forecast period 2025-2032, growing from USD 2.31 billion in 2024 to USD 6.68 billion in 2032. The theranostics market is poised for a revolutionary boom, led by increasing incidence of chronic conditions, especially cancer, increasing investments, and growing demand for targeted medicine. Advances in diagnostics and therapeutics also add to the precision of treatment, while a strong healthcare infrastructure and policy support drive innovation and availability in this fast-emerging sector.

Increased investments and financing in theranostics, particularly in university hospitals, are driving market growth by allowing innovative advancements in personalized medicine. These funds are spurring the creation of new diagnostic technologies and targeted therapeutic agents, as well as promoting translational research. Financial support also helps in public-private partnerships, accelerates approval from regulatory bodies, and increases access to theranostic solutions. In September 2024, the Theranostics Trial Center at Karolinska Institutet was granted USD 1.4 million by Vinnova, the Swedish government agency for innovation. the research institute aims to revolutionize cancer treatment in Sweden with image-guided diagnostics and radiolabeled targeted drugs, emphasizing theranostics market growth opportunities. The increasing investment demonstrates the global move towards precision healthcare, providing huge opportunities for market growth and better patient treatment outcomes.

The growing need for personalized therapies is one of the main factors driving the growth of the theranostics market, which is supported by the introduction of new theranostic products. In October 2024, Mediso Kft. introduced the AnyScan TRIO SPECT/CT, TheraMAX at the EANM meeting. It is intended for theranostic imaging purposes and was initially installed at University Hospital Regensburg, Germany. This release improves diagnostic confidence, like PET/CT, indicating substantial theranostics market growth by expanding nuclear medicine departments' imaging capabilities. This trend toward precision medicine is further supported by enhanced regulatory environments and increased partnerships between pharmaceutical firms and research organizations, making theranostics an essential strategy in personalized medicine and creating greater market opportunities.

Growing Government Initiatives and Investments Boost Market Demand

Government organizations are substantially elevating their investments in cancer care programs, fueling theranostics market demand. These investments will enhance healthcare infrastructure, develop comprehensive cancer centers, and improve access to high-tech diagnostic and treatment facilities, particularly in low, and middle-income nations. Governments in developed countries are also investing in improving cancer care.

In January 2025, Governor Kathy Hochul made a USD 188 million investment in seven hospitals throughout New York, United States. This is under the Healthcare Safety Net Transformation Program and involves the development of a cancer care center at Jamaica Hospital, as well as an upgrade of the emergency department at St. Barnabas Hospital. Moreover, other initiatives, such as the Rashtriya Arogya Nidhi in India aim to support poor cancer patients through financial aid, enabling them to receive specialist treatment. Intensified efforts are also being made globally to incorporate innovative solutions into national health systems, encouraging the adoption of personalized medicine strategies such as theranostics, which enable tailor-made treatments. All these advanced technologies are thereby changing cancer management practices globally.

Regulatory Support and Approvals Support Market Expansion

Increasing regulatory approvals of theranostic agents tremendously supports market expansion through increased awareness and acceptance of clinical applications. The FDA has created expedited procedures such as Breakthrough Therapy Designation and Fast Track Designation that speed up the review and approval process of emerging therapies for devastating diseases. This promotes quicker entry into the market and stimulates research and development investments. For example, new FDA approvals of innovative radiopharmaceuticals have broadened therapeutic opportunities, making targeted therapies with enhanced patient benefits possible.

In July 2024, the FDA approved Radiopharm Theranostics Limited's IND application for F18-Pivalate (RAD 101), a novel imaging agent, which is under investigation in clinical trials. RAD 101 aims to detect and characterize brain metastases. Moreover, the simplified approval processes and favorable regulatory support allow innovative theranostic solutions to be introduced to routine care more quickly. As such, these regulatory aids are essential to foster the growth of the theranostics market, allowing healthcare providers to deliver customized treatment choices corresponding to the increased focus on precision medicine.

Hospital End-user Segment to Dominate the Market

The hospitals segment will lead the theranostics market because of its advanced infrastructure, large patient flow, and adoption of precision medicine. Hospitals, especially multispecialty and tertiary care hospitals, utilize theranostics for customized oncology, cardiology, and neurology treatment, providing better diagnostic and therapeutic options. One of the trends is the partnership between university hospitals and major industry players, which supports research and clinical trials. These collaborations allow for state-of-the-art developments in radiopharmaceuticals, biomarkers, and imaging agents.

In June 2024, University Hospitals Cleveland and Siemens Healthineers extended their partnership to advance oncology, cardiovascular, and neurovascular treatment in Ohio, United States. They are targeting the development of Alzheimer's care and applying theranostics to treat late-stage cancers. This partnership with Case Western Reserve University is to create new magnetic resonance technologies, which will accelerate the growth of the theranostics market. University hospitals play a vital role in validating novel theranostics strategies, seeking funding, and bringing research into clinical practice. This collaboration substantially contributes to patient benefits by speeding the implementation of innovative therapies. These efforts highlight the increasing role of academic-commercial partnerships in developing theranostics as a foundation for personalized medicine.

North America Region Holds Major Market Share

North America dominates the theranostic market with a significant market share due to its strong healthcare infrastructure, high cancer incidents, and large-scale research activities. There is the presence of many key players in the region that dominate the market, driving innovation in radiopharmaceuticals, imaging agents, and targeted therapies. Increasing incidences of cancer, especially in the U.S. and Canada, increase demand for sophisticated diagnostic and therapeutic measures. North America is also a leader in research and development, with several clinical trials focusing on oncology, neurology, and cardiology. Governments and private entities are augmenting funding to support advancements in medical oncology at a faster pace, changing treatments and enhancing outcomes.

For instance, in January 2025, First Ascent Biomedical Inc. received an investment of USD 6 million from Vidal Duart Enterprises, Inc., co-invested by Techstars. This funding will further leverage their personalized cancer treatment for cancer patients, providing hope beyond conventional treatments and consolidating North America's strong lead in the expanding theranostics market. There is also higher awareness in the region of personalized medicine, which enables quicker acceptance of theranostic solutions. These combined factors further the position of North America as a leader in the world's theranostics market.

Future Market Scenario (2025 - 2032F)

The theranostics market growth is driven by technological innovation, combining diagnostic and therapeutic functions for precision medicine. Developments in nanotechnology, radiopharmaceuticals, and artificial intelligence-powered imaging are transforming disease treatment, especially in oncology, cardiology, and neurology. Rising investments in personalized medicine, cancer incidence, and academia-industry partnerships offer huge growth opportunities. Increasing healthcare infrastructure in developing countries further propels global adoption of theranostics, improving patient outcomes.

Several initiatives drive theranostics solution adoption. In November 2024, Thera4Care launched an initiative to position Europe as the leader in theranostics. By coordinating academic centers, healthcare professionals, SMEs, and industry, they seek to enhance radiotheranostics manufacturing and supply and create in-vitro cancer models. This multidisciplinary collaboration boosts healthcare preparedness and hints at substantial expansion prospects in the growing theranostics sector.

Technological innovations in theranostics are transforming precision medicine, fueling market expansion. The integration of theranostics with AI represents a revolutionary change, allowing radiologists to interpret medical images with unprecedented precision. AI augments diagnosis, streamlines treatment, and customized therapies, opening the potential for swift breakthroughs in cancer therapy and beyond. This convergence simplifies workflows, enhances patient care, and makes theranostics a foundation for future healthcare innovation, realizing vast market potential.

Key Players Landscape and Outlook

Key players in the theranostics industry are increasingly partnering with hospitals to perform clinical trials, emphasizing research and innovation. Such collaborations accelerate the growth of new theranostic solutions and allow for strategic mergers and acquisitions. Through these collaborations, companies seek to speed up the release and distribution of sophisticated diagnostic and therapeutic products, ultimately enhancing patient outcomes.

In October 2024, GE HealthCare and University Medicine Essen collaboratively opened a Theranostics Centre of Excellence in Germany with the aim of precision cancer care and widening access to more personalized therapies. The center will incorporate cutting-edge technologies and solutions, supporting GE HealthCare's market leadership with greater radioisotope production, more accurate diagnoses, and enhanced care coordination.

In September 2024, Telix Pharmaceuticals Limited bought RLS Radiopharmacies Inc. for USD 250 million. The acquisition, expanding Telix's U.S. network and supply chain strength, will increase major isotope production and provide a consistent supply of PET, SPECT, and therapeutic radiopharmaceuticals. The acquisition increases Telix's market reach and dramatically enhances its ability to address future demand, expanding its market base.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Theranostics Market Outlook, 2018-2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Product
      • 4.2.1.1. Radiopharmaceuticals
      • 4.2.1.2. Diagnostic Imaging
        • 4.2.1.2.1. Positron Emission Tomography (PET)
        • 4.2.1.2.2. Single Photon Emission Computed Tomography (SPECT)
        • 4.2.1.2.3. Others
      • 4.2.1.3. Software and Services
    • 4.2.2. By Application
      • 4.2.2.1. Oncology
        • 4.2.2.1.1. Breast Cancer
        • 4.2.2.1.2. Lung Cancer
        • 4.2.2.1.3. Colorectal Cancer
        • 4.2.2.1.4. Prostate Cancer
        • 4.2.2.1.5. Cervical Cancer
      • 4.2.2.2. Cardiovascular Diseases
      • 4.2.2.3. Neurological Disorders
      • 4.2.2.4. Immunological Disorders
      • 4.2.2.5. Other Applications
    • 4.2.3. By Technology
      • 4.2.3.1. Polymerase Chain Reaction (PCR)
      • 4.2.3.2. Immunohistochemistry (IHC)
      • 4.2.3.3. In Situ Hybridization (ISH)
      • 4.2.3.4. Next-Generation Sequencing (NGS)
    • 4.2.4. By End-user
      • 4.2.4.1. Hospitals
      • 4.2.4.2. Cancer Care Centers
      • 4.2.4.3. Diagnostic Laboratories
      • 4.2.4.4. Research and Academic Centers
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia-Pacific
      • 4.2.5.4. South America
      • 4.2.5.5. Middle East and Africa
    • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 4.3. Market Map Analysis, 2024
    • 4.3.1. By Product
    • 4.3.2. By Application
    • 4.3.3. By Technology
    • 4.3.4. By End-user
    • 4.3.5. By Region

5. North America Theranostics Market Outlook, 2018-2032F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Product
      • 5.2.1.1. Radiopharmaceuticals
      • 5.2.1.2. Diagnostic Imaging
        • 5.2.1.2.1. Positron Emission Tomography (PET)
        • 5.2.1.2.2. Single Photon Emission Computed Tomography (SPECT)
        • 5.2.1.2.3. Others
      • 5.2.1.3. Software and Services
    • 5.2.2. By Application
      • 5.2.2.1. Oncology
        • 5.2.2.1.1. Breast Cancer
        • 5.2.2.1.2. Lung Cancer
        • 5.2.2.1.3. Colorectal Cancer
        • 5.2.2.1.4. Prostate Cancer
        • 5.2.2.1.5. Cervical Cancer
      • 5.2.2.2. Cardiovascular Diseases
      • 5.2.2.3. Neurological Disorders
      • 5.2.2.4. Immunological Disorders
      • 5.2.2.5. Other Applications
    • 5.2.3. By Technology
      • 5.2.3.1. Polymerase Chain Reaction (PCR)
      • 5.2.3.2. Immunohistochemistry (IHC)
      • 5.2.3.3. In Situ Hybridization (ISH)
      • 5.2.3.4. Next-Generation Sequencing (NGS)
    • 5.2.4. By End-user
      • 5.2.4.1. Hospitals
      • 5.2.4.2. Cancer Care Centers
      • 5.2.4.3. Diagnostic Laboratories
      • 5.2.4.4. Research and Academic Centers
    • 5.2.5. By Country Share
      • 5.2.5.1. United States
      • 5.2.5.2. Canada
      • 5.2.5.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Theranostics Market Outlook, 2018-2032F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Product
          • 5.3.1.2.1.1. Radiopharmaceuticals
          • 5.3.1.2.1.2. Diagnostic Imaging
          • 5.3.1.2.1.2.1. Positron Emission Tomography (PET)
          • 5.3.1.2.1.2.2. Single Photon Emission Computed Tomography (SPECT)
          • 5.3.1.2.1.2.3. Others
          • 5.3.1.2.1.3. Software and Services
        • 5.3.1.2.2. By Application
          • 5.3.1.2.2.1. Oncology
          • 5.3.1.2.2.1.1. Breast Cancer
          • 5.3.1.2.2.1.2. Lung Cancer
          • 5.3.1.2.2.1.3. Colorectal Cancer
          • 5.3.1.2.2.1.4. Prostate Cancer
          • 5.3.1.2.2.1.5. Cervical Cancer
          • 5.3.1.2.2.2. Cardiovascular Diseases
          • 5.3.1.2.2.3. Neurological Disorders
          • 5.3.1.2.2.4. Immunological Disorders
          • 5.3.1.2.2.5. Other Applications
        • 5.3.1.2.3. By Technology
          • 5.3.1.2.3.1. Polymerase Chain Reaction (PCR)
          • 5.3.1.2.3.2. Immunohistochemistry (IHC)
          • 5.3.1.2.3.3. In Situ Hybridization (ISH)
          • 5.3.1.2.3.4. Next-Generation Sequencing (NGS)
        • 5.3.1.2.4. By End-user
          • 5.3.1.2.4.1. Hospitals
          • 5.3.1.2.4.2. Cancer Care Centers
          • 5.3.1.2.4.3. Diagnostic Laboratories
          • 5.3.1.2.4.4. Research and Academic Centers
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Theranostics Market Outlook, 2018-2032F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Theranostics Market Outlook, 2018-2032F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Theranostics Market Outlook, 2018-2032F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Theranostics Market Outlook, 2018-2032F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Siemens Healthineers AG
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. Cardinal Health Inc.
    • 20.3.3. GE HealthCare Technologies Inc.
    • 20.3.4. Telix Pharmaceuticals Limited
    • 20.3.5. Jubilant Pharmova Limited (Jubilant Radiopharma)
    • 20.3.6. Radiopharm Theranostics Limited
    • 20.3.7. Lantheus Holdings, Inc.
    • 20.3.8. Curium Pharma UK Ltd
    • 20.3.9. Cardio Theranostics LLC
    • 20.3.10. Ariceum Therapeutics GmbH

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer